Clinical Application of Detecting 21-Gene Recurrence Score in Predicating Prognosis and Therapy Response of Patients with Breast Cancer from Two Medical Centers

ABSTRACT

To determine the most suitable strategy in treating patients with invasive breast cancer from Northwest China. Lower recurrence score (RS) correlated with lower recurrence ratio. Patients having a medium-high 21-gene RS who received adjuvant therapy presented lower recurrence risk. Younger patients having RS results (⩾31) tended to accept adjuvant therapy more often, however, those having intermediate RS results were inclined to wait and did not receive chemotherapy. These results suggested that RS-based precision medicine will allow individualized diagnosis and treatment, resulting in better outcomes and preserved medical resources.

KEYWORDS:

• Breast cancer
• 21-Gene recurrence score
• Cancer stem cells
• Recurrence risk

Acknowledgments

The authors acknowledged assistants in the Center for Translational Medicine, the First Affiliated Hospital of Xi'an Jiaotong University, and the Institute of Urinary Surgery (the Key Laboratory, Ministry of Education), the First Affiliated Hospital of Xi'an Jiaotong University.

Conflicts of interest statement

All co-authors implicated in this research approved this article to be published. The authors declare that they have no conflict of interest.

Funding

This experiment was mainly supported by National Natural Science Foundation for Young Scientists of China, grant No. 81602597 (Referred to Xin Sun), National Natural Science Foundation of China, grant No. 81272418 (Referred to Hong Ren). This work was also supported in part by National Natural Science Foundation for Young Scientists of China, grant No. 81402506 (Referred to Sida Qin), Natural Science Foundation of Shaanxi Province, grant No. 2016JM8007 (Referred to Jing Zhang).